Albert Science International Organization

ABSTRACT

By the 1950s, kidney disease was clearly recognized as a common complication of diabetes, with as many as 50% of patients with diabetes of more than 20 years having this complication. Currently, diabetic nephropathy is the leading cause of chronic kidney disease in the United States and other Western societies. It is also one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes. Diabetes is responsible for 30-40% of all end-stage renal disease (ESRD) cases in the United States. Generally, diabetic nephropathy is considered after a routine urinalysis and screening for micro-albuminuria in the setting of diabetes. Patients may have physical findings associated with long-standing diabetes mellitus. Good evidence suggests that early treatment delays or prevents the onset of diabetic nephropathy or diabetic kidney disease. Regular outpatient follow-up is key role in managing diabetic nephropathy successfully. Type II diabetes is a significant health concern in the United States and its prevalence is expected to triple by 2050. Both metformin and exercise have shown to be effective in the management of blood glucose control. Both metformin and exercise have a positive and significant role in the management of type 2 diabetes and appear to work similarly to help manage blood glucose control. Recent clinical trials like Magnetic Molecular Energizer (MME), Bi-Axial Rotating Magnetic Field Therapy are some of the treatment which under trials. This will be lead to great discovery in this field. This can be useful step towards treating a major complication of diabetic and to save diabetic people from severe disease.

Keywords: Magnetic Molecular Energizer (MME), Bi-Axial Rotating Magnetic Field Therapy, Diabetic Neuropathy, micro-albuminuria.